Gilead Commits $11 Billion to U.S. Manufacturing Expansion to Counter Tariff Pressures
Gilead Sciences has announced an $11 billion investment to enhance its U.S. manufacturing and research capabilities. This move is in response to anticipated tariffs from the Trump administration, which is currently investigating the pharmaceutical sector. The investment is part of a broader industry trend, with companies like Johnson & Johnson, Merck, and Novartis collectively pledging […]
Continue Reading